

Supporting Information

***In Vivo* Pharmacokinetic and Pharmacodynamic Profiles of Antofloxacin against *Klebsiella pneumoniae* in a Neutropenic Murine Lung Infection Model**

Yu-Feng Zhou^{a,b}, Meng-Ting Tao^{a,b}, Wei Huo^{a,b}, Xiao-Ping Liao^{a,b}, Jian Sun^{a,b} and
Ya-Hong Liu^{a,b*}

^a National Risk Assessment Laboratory for Antimicrobial Resistance of Animal
Original Bacteria, South China Agricultural University, Guangzhou, China;

^b Guangdong Provincial Key Laboratory of Veterinary Pharmaceutics Development
and Safety Evaluation, South China Agricultural University, Guangzhou, China;

*** Corresponding author:**

Ya-Hong Liu, PH.D., Laboratory of Veterinary Pharmacology, College of Veterinary
Medicine, South China Agricultural University, Guangzhou, P. R. China. E-mail:

lyh@scau.edu.cn. Tel: +86-020-85280006; Fax: +86-020-85280006

Supplementary Materials & Methods

Sample processing and LC-MS/MS method

A 0.1 mL aliquot of plasma sample or BAL fluid was transferred into a capped centrifuge tube, and then mixed with 0.1 mL of acetonitrile. After vortexing (1 min) and centrifuging ($12000 \times g$, 10 min), the supernatant was filtered through a $0.22 \mu\text{m}$ nylon syringe filter and collected into a sample vial for concentration determination. The drug concentration analyses were performed using a HPLC-ESI-MS/MS system (Agilent 1200 HPLC system; Agilent Technologies, Santa Clara, CA, USA; API 4000 triple quadrupole mass spectrometer; Applied Biosystems, Carlsbad, CA, USA) equipped with a short column (Waters Symmetry C18, $2.1 \times 50 \text{ mm}$, $3.5 \mu\text{m}$). The injection volume was $5 \mu\text{L}$, and column temperature should be maintained at $30 \text{ }^\circ\text{C}$. The mobile phase consisted of (A) acetonitrile and (B) 0.1% formic acid in water containing 2 mM ammonium acetate using a gradient elution with a flow rate of $200 \mu\text{L}/\text{min}$: 0-0.5 min (5% A), 0.5-3.5 min (5-85% A), 3.5-4.0 min (85% A), 4.0-4.5 min (85-5% A), 4.5-11 min (5% A). The total run time was 11 min. The mass conditions were as follows: ionspray voltage, 5000 V; curtain gas, 20 psi; nebulizer gas, 55 psi; collision gas, 20 psi; source temperature, $600 \text{ }^\circ\text{C}$. Ion transitions of m/z $377.2 \rightarrow 333.2$ and $377.2 \rightarrow 276.1$ were chosen for multiple reaction monitoring (MRM) experiments in positive mode. The correlation coefficients (r) were above 0.999 in the linear range of 0.01 - $0.5 \mu\text{g}/\text{mL}$. All samples that had concentrations above $0.5 \mu\text{g}/\text{mL}$ were diluted proportionally prior to extraction with acetonitrile. The limit of quantification (LOQ) and detection (LOD) were 0.01 and $0.005 \mu\text{g}/\text{mL}$, respectively. Mean extraction

recoveries from the five replicate assays were $88.9 \pm 7.96\%$, $91.2 \pm 7.05\%$ and $96.7 \pm 5.71\%$ at spiked drug concentrations of 0.02, 0.2, and 2 $\mu\text{g/mL}$, respectively. The intraday coefficients of variation for replicate control samples ($n = 5$) within these concentration ranges varied from 2.2 to 8.7%, and the interday coefficients of variation ranged from 5.9 to 9.7%.

Supplementary Table

Table S1. Protein binding of antofloxacin in murine plasma at three spiked levels ^a

Spiked levels (mg/L)	Binding (%) ^b
0.05	18.6 ± 2.38
0.5	20.2 ± 0.72
5	22.3 ± 1.02

^a Values are means \pm standard deviation; $n = 3$.

^b The plasma protein binding of antofloxacin is 20.3% for mice determined in the present study, which was similar to the values of 17.5% for humans (1, 2).

References

1. **Yu X, Wang G, Chen S, Wei G, Shang Y, Dong L, Schon T, Moradigaravand D, Parkhill J, Peacock SJ, Koser CU, Huang H.** 2016. Wild-Type and Non-Wild-Type *Mycobacterium tuberculosis* MIC Distributions for the Novel Fluoroquinolone Antofloxacin Compared with Those for Ofloxacin, Levofloxacin, and Moxifloxacin. *Antimicrob Agents Chemother* **60**:5232-5237.
2. **Liu L, Pan X, Liu HY, Liu XD, Yang HW, Xie L, Cheng JL, Fan HW, Xiao DW.** 2011. Modulation of pharmacokinetics of theophylline by antofloxacin, a novel 8-amino-fluoroquinolone, in humans. *Acta Pharmacol Sin* **32**:1285-1293.